Compare Impinj Inc (PI) vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Impinj Inc vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) — how do they compare? Impinj Inc trades at $188.02 (market cap $5.60B), while Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $18.35 (market cap $58.74B). The key difference: Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) is far larger — about 10.5× Impinj Inc's market cap, and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) pays a 3.33% dividend while Impinj Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Impinj Inc for 22 Days and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) for 0 Days on average.
| PI | TAK | |
|---|---|---|
Market Cap | $5.60B | $58.74B |
Volume | 9,929 | 3,110,994 |
Sector | Technology | Health |
52-Week High | $241.91 | $19.05 |
52-Week Low | $91.34 | $13.23 |
Typical Hold Time | 22 Days | 0 Days |
Enterprise Value | $5.73B | $86.65B |
Dividend Yield | — | 3.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Impinj (PI) trades at $191.04, up 3.81% today, showing strong momentum with a bullish technical signal from moving averages. The stock has beaten earnings estimates in recent quarters, with Q2 2026 EPS of $0.86 exceeding expectations. However, the company remains unprofitable with a net income margin of -7.26% for 2026. Analyst consensus is strongly positive with 16 buy ratings and a $178.83 price target, though the current price exceeds this target. Recent news highlights the CFO's stock sale and participation in industry conferences.
The outlook for PI is mixed; strong revenue growth and bullish analyst sentiment support upside, but profitability challenges and high valuation ratios pose risks. Investment opportunity lies in the company's positioning in RFID technology, while key risks include sustained losses and competitive pressures. The stock's proximity to resistance at $192 suggests near-term volatility.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Impinj Inc
Impinj, Inc. is a leading provider of RAIN RFID (radio-frequency identification) solutions. The company's platform includes endpoints (tag chips), connectivity devices (readers and gateways), and software, enabling businesses to wirelessly identify, locate, and authenticate everyday items. Impinj's technology is crucial for applications in retail, supply chain management, healthcare, and logistics, helping businesses to automate inventory, track assets, and improve operational efficiency.
Read more on PI →About Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.
Read more on TAK →
